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1. Introduction 
Endometriosis is a benign gynaecological disease characterized by the presence of 
endometrial glands and stroma outside the uterine cavity. This condition is mainly found in 
women of reproductive age, from all ethnic and social groups and it is associated with 
pelvic pain and infertility. Endometriosis is typically present in the pelvis such as on the 
ovaries and pelvic peritoneum, but may also involve the bowel, ureter or bladder. It 
regresses after menopause or ovariectomy, suggesting it could depend on the production 
and metabolism of sex steroids: high concentrations of estrogens were found in the 
endometriotic lesions, which grow and regress in an oestrogen-dependent way. 
Nevertheless, the pathogenesis and the molecular mechanism that underlie the 
development of endometriosis have troubled the investigators through many years, 
remaining an enigma. The disease is widely accepted to result from the ectopic implantation 
of refluxed menstrual tissues. In addition, immunologic changes, environmental, hormonal 
and genetic factors contribute to the multifactorial etiology of endometriosis.  
Many studies are therefore focusing on identifying markers for the diagnosis and follow-up 
of endometriosis. Although the ‘‘gold standard” for the diagnosis of endometriosis is the 
laparoscopy, many reports have suggested that various serum, peritoneal fluid and tissue 
markers might be associated with endometriosis. In fact, the identification of more sensitive 
and specific markers of endometriosis should facilitate the development of accurate and 
non-invasive techniques for diagnosis and prognosis (Table 1). Furthermore, the inheritable 
susceptibility to endometriosis justifies the growing interest in identifying genes and/or 
genetic polymorphisms that could lead to an increased risk of disease. Identifying these 
polymorphisms may open to their use as genetic biomarkers of endometriosis.  
Over the last 20 years, several proteomics technologies have been used to research novel 
proteins with a potential etiological role in endometriosis, and to identify candidate serum 
markers for this condition. While some molecules identified by proteomics technologies 
may have a relevant role in the pathogenesis of endometriosis, the research of potential 
serum markers for this condition is still far from any clinical application. 
The early diagnosis of endometriosis could prevent the possible progression of 
endometriosis, resulting in more pain, infertility and in a declining quality of life.  
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For a clinical purpose, the identification of highly sensitive and specific diagnostic test of 
endometriosis should facilitate the development of accurate and non-invasive test diagnosis 
and prognosis. 
PERITONEAL FLUID AND/OR  
SERUM MARKERS 
Glycoproteins 
Growth factors 
Cytokines 
Autoantibodies 
Hormones 
Proteolytic enzymes and their inhibitors 
Soluble adhesion molecules 
Environmental contaminant 
ENDOMETRIAL MARKERS Cell adhesion molecules (CAMs) 
Proteolytic enzymes 
ENDOMETRIAL TISSUE 
BIOCHEMICAL MARKERS 
Aromatase P450 
Hormone receptors 
GENETIC MARKERS Survivin gene expression 
p53 mutations 
Polymorphisms 
Table 1. Markers for endometriosis 
2. Peritoneal fluid and/or serum markers 
Many serum and peritoneal fluid markers can be used to discriminate between patients with 
or without endometriosis (Table 2). Using markers with a high degree of sensitivity and 
specificity for endometriosis it is possible the development of peritoneal fluid and /or 
serum based diagnostics tools, therapeutic strategies and prognosis markers. 
 
GLYCOPROTEINS CA125 
CA19-9 
GROWTH FACTORS Hepatocyte growth factor (SF/HGF) 
Fibroblast growth factor (FGF) 
Epidermal growth factor (EGF) 
Transforming growth factor-alpha (TGF-α) 
Transforming growth factor-beta (TGF-β) 
Vascular endothelial growth factor (VEGF) 
Epidermal growth factor receptor (EGF-R) 
Insulin-like growth factor I (IGF-I) 
CYTOKINES TNF-α 
IL-1 
IL-6 
IL-8 
Monocyte chemoattractant protein (MCP)-1 
Interferon-γ 
Table 2. Peritoneal fluid (PF) and/or serum markers for endometriosis 
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AUTOANTIBODIES 
 
Antiendometrial antibodies  
Autoantibodies to oxidized lipoproteins 
Thyroid peroxidase antibodies 
IgG anti-laminin-1 antibodies 
Anti-phospholipid antibodies 
HORMONES Luteinizing hormone (LH) 
Progesterone 
Estradiol 
Thyroid stimulating hormone (TSH) 
Follicle stimulating hormone (FSH) 
Leptin 
PROTEOLYTIC ENZYMES AND  
THEIR INHIBITORS 
Matrix metalloproteinases (MMPs) 
Tissue inhibitors for MMPs (TIMPs) 
SOLUBLE ADHESION MOLECULES  
 
Intercellular adhesions molecule-1 (sICAM-1) 
Human leukocyte class I antigens (sHLA-I) 
E-cadherin 
ENVIRONMENTAL CONTAMINAT Dioxin-like chemicals 
Table 2. Peritoneal fluid (PF) and/or serum markers for endometriosis. (Continuation) 
2.1 Glycoproteins 
Some serum glycoproteins, more commonly known for its use in the diagnosis or 
monitoring of cancers, might also serve as a marker for endometriosis, although levels are 
usually elevated only in advanced stages and are therefore not suitable for routine 
screening. 
2.1.1 CA125 
CA125 is a 200,000 Da glycoprotein expressed on the surface of the coelomic epithelium, 
including the epithelium of the endocervix, endometrium, fallopian tube, pelvic peritoneum 
and placental tissues. Serum CA125 levels increase in patients with malignant and benign 
gynaecologic diseases, including endometriosis.  
Despite the most important clinical use of CA125 is the monitoring of patients with ovarian 
cancer, high levels can be found in women with endometriosis. Many studies have assessed 
the role of CA125 serum levels in women affected with endometriosis. The sensitivity and 
specificity of serum CA125 assay varies with the stage of disease. Usually, high CA125 
serum levels can be found both in most patients with advanced endometriosis and in few 
patients with early-stage disease. Therefore, the routine use of serum CA125 cannot be used 
as a diagnostic tool for endometriosis. Serum CA125 may be more useful in evaluating 
recurrent disease or the outcome of a surgical treatment. CA125 levels may also be useful in 
patients with advanced endometriosis and several studies have suggested the use of this 
marker in the preoperative diagnosis of endometriosis.  
The patients with endometriosis often undergo repeated laparoscopic examinations to 
assess the progress during and after therapy or to determine the recurrence of disease. 
Therefore, CA125 may be useful in the management of endometriosis and some authors 
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suggest its assessment in women with suspected endometriosis, in association with 
laparoscopy and biopsy. In addition, in literature was reported that measurement of serum 
CA125 levels might be useful in identifying patients with infertility that may have severe 
endometriosis and could benefit from early surgical treatment. 
CA125 levels were assessed in the PF of patients with and without endometriosis. Although 
levels of CA125 in the PF were almost 10 times higher than serum levels, no differences 
were found between women with and without endometriosis. In addition, CA125 levels are 
measured also in other body fluids, such as menstrual discharge and the uterine fluid, but 
are not useful in clinical practice. 
2.1.2 CA19-9 
CA19-9 is a high-molecular-weight glycoprotein that was initially thought to be an 
oncofetal antigen. Serum CA19-9 levels were elevated in patients with some malignant 
tumour, such as gastrointestinal adenocarcinoma, pancreatic carcinoma, or lung 
carcinoma; thus, the measurement of serum CA19-9 levels is useful in the diagnosis of 
these tumours. In gynaecology, the serum CA19-9 levels are elevated in patients with 
malignant and benign ovarian tumours. Furthermore, a case of an ovarian chocolate cyst 
with a markedly elevated serum CA19-9 level has been reported. In addition, it has been 
reported that serum CA19-9 levels in women with endometriosis are significantly reduced 
during therapy compared with the basal levels before treatment. Serum CA19-9 levels in 
patients with endometriosis are significantly higher than those in patients without 
endometriosis and that serum CA19-9 levels increase in accordance with the advancement 
of the clinical stage of endometriosis. CA19-9 was also detected in the endometrial 
glandular epithelium in ovarian chocolate cysts by immunohistochemistry. These results 
reveal that the measurement of the serum CA19-9 levels, as well as the serum CA125 
level, may prove to be a valuable tool for predicting the severity of endometriosis as 
diagnosed by laparoscopy. 
2.2 Growth factors 
The endometrium in endometriosis behaves like tumorous tissue and the growth factors 
involved in tumour proliferation, angiogenesis and invasiveness have been investigated for 
their expression in endometriosis. Indeed, the degree of endometriosis is positively 
correlated with the concentration in peritoneal fluid and serum of Hepatocyte Growth 
Factor/Scatter Factor (HGF/SF), a multifunctional polypeptide that has been implicated in 
embryo development, tissue repair, and cancer growth, produced mainly by mesenchymal 
cells with activity mediated through the c-met receptor found principally on epithelial and 
endothelial cells (Zong et al., 2003). 
Inflammatory macrophages and the inflammatory mediators they release could be related to 
the ectopic implantation of endometriosis: Fibroblast Growth Factor (FGF), Epidermal Growth 
Factor (EGF), Transforming Growth Factor-alpha (TGF-α), Transforming Growth Factor-beta 
(TGF-β) and Tumor Necrosis Factor-alpha (TNF- α). It is been shown that these growth factors 
stimulate in vitro proliferation of endometrial stromal cells, suggesting that they could 
improve the implantation of endometrial cells.  
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Elevated serum levels of Epidermal Growth Factor Receptor (EGF-R), involved in angiogenesis, 
suggest an active role for EGF in the development of endometriosis (Matalliotakis et al., 
2003a, 2003b). 
Insulin-like Growth Factor I (IGF-I) serum levels in patients with early stage endometriosis, 
and in healthy control, were significantly lower than the levels in patients with late stage 
endometriosis, suggesting that IGF-I is an important mediator in the development and/or 
maintenance of endometriosis or progression to late stage disease (Gurgan et al., 1999). 
Many studies report that angiogenesis is probably involved in the pathogenesis of 
endometriosis. Vascular endothelial growth factor (VEGF), also known as vascular permeability 
factor, is one of the most potent and specific angiogenic factors. VEGF has emerged as an 
important regulator of normal angiogenesis and pathological neovascularisation.  
VEGF levels in both peritoneal fluid and serum were higher in women with endometriosis 
compared with controls. The cellular source of VEGF in peritoneal fluid has not yet been 
precisely defined. Some evidence suggests that the endometriotic lesions themselves 
produce this factor and that the activated peritoneal macrophages are able to synthesize and 
secrete VEGF (Matalliotakis et al., 2003a, 2003b). 
2.3 Immunological markers 
The immune system plays an important role in the pathogenesis of endometriosis, which 
begins, therefore, to be treated as an autoimmune disease. T-helper, T-suppressor and 
natural killer (NK) cells concentrations are altered in serum and peritoneal fluid of patients 
with endometriosis (Lebovic et al., 2001; Nothnick, 2001). In addition, IgG and IgA anti-
endometrial antibodies have been detected in the sera and vaginal and cervical secretions of 
endometriosis patients. The presence of anti-phospholipids and anti-histones antibodies has 
been documented by some authors and questioned by others. These observations would 
believe that markers of immune reactivity, particularly cytokines, might be used as a 
diagnostic aid for endometriosis. 
2.3.1 Cytokines  
Macrophages are a major source of many cytokines involved in immune response, 
haematopoiesis, inflammation and many other homeostatic processes. Upon stimulation by 
microorganisms, microbial products or endogenous factors including cytokines, 
macrophages can de novo synthesize and release a large variety of cytokines (i.e. IL-1, IL-1ra, 
IL-6, IL-8, IL-10, IL-12, TNF-α, IFN-α, IFN-γ, MCP-1, MCP-3, MIF, M-CSF, G-CSF, GM-CSF, 
MIP-1, MIP-2, LIF, OSM, TGF-β). Some cytokines can up-regulate the production of 
cytokines by macrophages (IL-3, GM-CSF, IFN-γ) while others can inhibit it (IL-4, IL-10, IL-
13, TGF-β). In addition, these cytokines can modulate most of the macrophage functions and 
cell surface marker expression. Other cytokines (chemokines such as MCP-1, 2, 3, MIP-1,2 
and RANTES) contribute to the recruitment of circulating monocytes within tissues.  
T lymphocytes are important regulatory cells that secrete several cytokines and participate 
actively in this inflammatory response. According to the pattern of cytokines secreted, the 
immune response is classified as cytotoxic or type 1 (IFN-γ, IL-2, IL-12) and humoral or type 
2 (IL-4, IL-5, IL-10 and IL-13) (Barcelò et al., 2006). 
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The role of cytokines and growth factors in the pathophysiology of endometriosis is evident. 
They are probably responsible for the proliferation of endometrial cells and implantation of 
endometrial cells or tissue. In addition, cytokines increase the tissue remodelling through 
their influence on matrix metalloproteinases. Probably the most important effect of 
cytokines on ectopic endometrial tissue is an increase in angiogenesis of ectopic endometrial 
tissue and neovascularisation of the affected region. Therefore, cytokines play an important 
role in the initiation, propagation and regulation of immune and inflammation responses. 
The activation of immune cells results in a burst and cascade of inflammatory cytokines. 
ELISA kits are available to assess the cytokines in the serum and peritoneal fluid (PF) of 
endometriosis patients. PF is rich with variable cellular components including macrophages, 
mesothelial cells, lymphocytes, eosinophils and mastcells. Approximately 85% of PF 
leukocytes are macrophages. It has been hypothesized that peritoneal macrophage 
activation is a key step in disease initiation and progression. Activated macrophages in the 
peritoneal cavity of women with endometriosis are potent producers of cytokines (Bedaiwy 
et al., 2002). Thus, PF contains a rich mixture of cytokines. Cytokines, such as TNF-α, IL-1, 
IL-6, IL-8, monocyte chemoattractant protein (MCP)-1 and IFN-γ, are elevated in the PF of 
women with endometriosis, suggesting that they are involved in the progression of the 
disease. The level of IL-1 in PF is positively correlated with the progression of 
endometriosis, but the serum level of IL-1 seems to have no correlation with endometriosis. 
The Tumor Necrosis Factors (TNF) superfamily of cytokines represents a multifunctional 
group proinflammatory cytokines, which activate signalling pathways for cell survival, 
apoptosis, inflammatory responses, and cellular differentiation. Induction of cellular 
responses to TNF occurs through two receptors, TNFR1 (TNF Receptor-1 or CD120a) and 
TNFR2 (TNF Receptor-2 or CD120b). TNFR1 is activated in most human tissues by the 
binding of TNFα. On the other hand, TNFR2 is primarily expressed in immune cells and is 
activated by both TNFα and TNFβ (Kawasaki et al., 2002).  
The main TNF is TNF-α, which is produced by neutrophils, activated lymphocytes, 
macrophages, NK cells and several non-hematopoietic cells. The TNF-α is involved in the 
normal physiology of the endometrial proliferation in the human endometrium. TNF-α is 
expressed predominantly in epithelial cells, especially in the secretory phase. The stromal 
cells stain for TNF-α mostly in the proliferative phase of the menstrual cycle. These data 
suggest that hormones influence the role of this cytokine. 
Some reports found that concentrations of TNF-α in both serum and PF were very high at 
the early stage of the disease and decreased with the severity of the endometriosis. 
Moreover, the assessment of TNF-α levels in the PF can be used as a basis for non-surgical 
diagnosis of endometriosis.  
The role of IL-6 in the pathogenesis of endometriosis has been widely studied. IL-6 is a 
regulator of inflammation and immunity, which may represent a physiological link between 
the endocrine and immune systems. IL-6 also modulates the secretion of other cytokines, 
promotes T-cell activation, differentiation of B cells and inhibits the growth of several 
human cell lines (Nothnick, 2001).  
The data about IL-6 levels in the PF of patients with endometriosis are controversial. In fact, 
no statistically significant differences are reported between controls and endometriosis 
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patients. In contrast, serum levels of IL-6 were significantly higher in women with 
endometriosis than in controls and the highest levels were found in women with chocolate 
cysts (Wieser et al., 2003; Iwabe et al., 2003).  
2.3.2 Autoantibodies 
Endometriosis is supposed to be an autoimmune disorder and many autoantibodies have 
been proposed as a diagnostic test. A variety of autoantibodies have been detected in 
endometriosis patients (thyroid peroxidase antibody, IgG anti-laminin-1 antibodies, anti-
phospholipid antibodies and the novel anti-PDIK1L antibodies). The most commonly 
reported types are antiendometrial antibodies, autoantibodies against the oxidative-stress-
induced, antigens to malondialdehyde-modified low-density lipoprotein (LDL) and 
oxidized low-density lipoprotein (Ox-LDL). 
Some investigators have hypothesized that antiendometrial antibodies may cause 
infertility in some women with endometriosis by preventing the fertilized embryo from 
implanting in the uterus. In addition, increasing evidence suggests that oxidative stress 
occurs in the PF of women with endometriosis and oxidatively modified lipoproteins 
were found in the PF.  
2.4 Hormones 
Serum and PF hormones levels vary in patients affected with endometriosis. Luteinizing 
hormone (LH) levels are significantly higher in both serum and PF in patients with 
endometriosis than in normal controls (Illera et al., 2001). However, levels of prolactin, 
thyroid stimulating hormone (TSH) and follicle stimulating hormone (FSH) in the serum 
were no different between the different groups.  
Recently it was reported that serum concentrations of leptin are increased in patients with 
endometriosis. This increase may play an anti-apoptotic role in activated endometrial 
stromal cells into the peritoneal cavity, stimulating endometrial cell implantation and cause 
infertility (Tanaka et al., 2003). Furthermore another study measured the serum 
concentration of leptin using a radioimmunoassay method, showing a significant 
association between leptin concentrations and stage of endometriosis (Viganò et al., 2002).  
2.5 Proteolytic enzymes and their inhibitors 
The physiological changes in endometriosis involve multiple steps of matrix remodelling. 
Endometriosis associated to abnormal matrix remodelling is affected by several molecular 
factors including proteolytic enzymes and their inhibitors, which mediate tissue turnover, 
and ovarian steroids, which normally regulate reconstruction of endometrium in the 
menstrual cycle.  
The extracellular matrix (ECM) constitutes a well-organized network structure that 
surrounds the cells. The tissue remodelling involving ECM turnover is regulated by the 
pooled action of proteolytic enzymes, matrix metalloproteinases (MMP) and tissue 
inhibitors for MMP (TIMP). The inappropriate expression of MMP and TIMP is associated 
with tumorigenesis and metastasis, as well as with endometriosis.  
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Several MMP have been implicated in the development of endometriosis (Sillem et al., 2001). 
The levels of MMP and TIMP in patients with endometriosis are different depending on the 
method of measurement and collection of samples of different tissues at different stages of 
endometriosis. The values of TIMP-1 is determined by radioimmunoassay measurement in 
serum of patients with PF in endometriosis are lower than in controls. In contrast, the 
concentration of TIMP-1 was restored after treatment with gonadotropin releasing hormone.  
Another study reported that there was no significant difference in levels of cathepsin D, a 
proteolytic enzyme thought to promote digestion of ECM proteins in endometriosis, in 
serum from women with and without endometriosis. 
2.6 Soluble adhesion molecules 
It is thought that the retrograde flow of the menstrual debris to the peritoneal cavity plays 
an important role in the origin of endometriosis but the mechanism of endometrial cells 
implantation remains unknown. Recently many studies have reported the importance of 
adhesion molecules in this process. 
Several adhesion molecules (CAM) are expressed in the human endometrium: i.e. integrins, 
cadherins and immunoglobulin superfamilies. These adhesion molecules show cyclical 
changes during the menstrual cycle. The major cell surface receptors of the ECM are the 
integrins that contain large (ǂ) and small (ǃ) subunits. 
ǃ1-integrins are known to mediate the interaction between the cell-cell and cell-extracellular 
matrices and are represented by very late activation (VLA) antigen molecules. It is well 
known that endometriosis is frequently associated with immunological abnormalities. 
However, only a few studies have been conducted on the adhesion molecules, particularly 
on ǃ 1-integrins, in endometriosis. It has reported that integrins are expressed in the 
endometrium in endometriosis. The ability of endometriotic tissues to express integrins may 
explain the high recurrence rates in patients with endometriosis, as these samples retain 
their adhesion potency after retrograde menstruation and are thus able to establish cell-cell 
and cell-matrix interactions with the surrounding peritoneum. 
The soluble forms of the intercellular-adhesion molecule-1 (sICAM-1) are secreted from the 
endometrium and endometriotic implants. Moreover, endometrium from women with 
endometriosis secretes a higher amount of this molecule than tissue from women without 
the disease. Consequently, a strong correlation exists between levels of sICAM-1 and the 
number of endometriotic implants in the pelvis. Therefore, it has been hypothesized that 
sICAM-1 may be useful in the diagnosis of endometriosis (Leng et al., 2002). Many 
investigators have reported a significant increase in serum concentration of sICAM-1 in 
patients with endometriosis. The sICAM-1 concentrations were higher in patients with stage 
I−II endometriosis, suggesting that studies on these soluble adhesion molecules can help 
clarify the pathogenic mechanisms of endometriosis. Elevated ICAM-1 levels were found in 
patients with severe endometriosis, but its sensitivity is not high and the concomitant use of 
the CA125 marker increases the sensitivity and specificity of detection (Somigliana et al., 
2002).  
The E-cadherin mediates cell-cell interaction and cells adhere preferentially to cells that 
express the same cadherin. Cadherins are distributed widely among animals and play a 
potentially significant role in morphogenetic events during embryogenesis. Cadherin is also 
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expressed in the cell-to-cell boundaries of the endometrium. It is reported that E-cadherin 
expression on the endometrium was higher in the secretory phase than in the proliferative 
phase, although there is one report that the expression was unchanged during the cycle. 
Furthermore, the level of E-cadherin in serum of endometriosis patients was significantly 
higher than that of control group.  
The level of E-cadherin in the serum of both III stage and IV stage endometriosis patients 
was higher than that of I and II stage patients. However, the difference between them was 
not statistically significant. E-cadherin may play a role on the morbidity of endometriosis 
and the serum E-cadherin assay might be helpful as a serum marker for the diagnosis and 
management of endometriosis (Fu & Lang, 2002).  
2.7 Environmental contaminant 
Environmental toxins, such as dioxins and polychlorinated biphenyls are some of the factors 
that have been suggested to play a significant role in the development of endometriosis. In 
fact, detection of environmental contaminant residues in serum and ovarian follicular fluid 
confirms this hypothesis. Dioxin-like chemicals, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) and polyhalogenated aromatic hydrocarbons (PHAHs), may exert effects on the 
pathophysiology of endometriosis through a number of pathways: (1) activation of pro-
carcinogens; (2) altered synthesis and metabolism of estradiol; (3) altered production of pro-
inflammatory growth factors or cytokines and (4) alterations in tissue remodelling 
processes. 
Exposure to HAHs and TCDD seems to be associated with a dose-dependent increase in the 
incidence and severity of endometriosis. TCDD may target peripheral blood and peritoneal 
and endometrial leukocyte populations inducing chronic expression of TNF-α and other 
inflammatory mediators resulting in increased adhesion, vascularization and proliferation 
of endometriotic cells. It has been suggested that an elevated concentration of TNF-a might 
participate in TCDD-mediated toxicity and contribute to the pathogenesis of endometriosis.  
Dioxins may affect the expression of TNF-α via the induction of an inflammatory cytokine 
network, since the region of DNA that recognize the ligand-activated AhR, the dioxin-
response element of DRE, is present in the genes of potent inducers of TNF-α including IL-
1b, IL-6 and IFN-γ (Rier & Foster, 2003). 
3. Endometrial markers  
The adhesion of endometrial cells to the extracellular matrix (ECM) would be expected to 
play a central role in the pathogenesis of endometriosis. Various cell adhesion molecules 
(CAMs) have been investigated for their expression in endometriotic endometrium. Each 
cell type expresses a distinct pattern of integrins and other CAMs, including the cadherins, 
selectins and members of the immunoglobulin family that determines cell shape, maintains 
cell position and polarity and affects hormonal responsiveness. In addition, apoptosis might 
be mediated through loss of appropriate signals from the ECM through alternations in the 
integrin expression. Based on cell adhesion and the genes involving in adhesion and 
invasion aspects, cell adhesion molecules (CaMs) and proteolytic enzymes were investigated 
for their mechanisms in association with the progression of endometriosis. 
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4. Endometrial tissue biochemical markers 
4.1 Aromatase P450 
Aromatase P450 is the key enzyme for biosynthesis of oestrogen, which is an essential 
hormone for the establishment and growth of endometriosis. There is no detectable 
aromatase enzyme activity in normal endometrium; therefore, oestrogen is not locally 
produced in endometrium. Endometriosis tissue, however, contains very high levels of 
aromatase enzyme, which leads to production of significant quantities of oestrogen 
(Dheenadayalu et al., 2002). Moreover, one of the best-known mediators of inflammation 
and pain, prostaglandin E2 (PGE2), was found to be the most potent known inducer of 
aromatase activity in endometriotic stromal cells. The clinical significance of local aromatase 
activity that is induced strikingly by PGE2 in endometriotic tissue was exemplified recently 
by the successful use of an aromatase inhibitor to treat an unusually aggressive case of 
recurrent postmenopausal endometriosis that was resistant to any other surgical or 
hormonal modalities of treatment. Therefore, the aberrant expression of aromatase P450 in 
endometriotic tissue, in contrast to eutopic endometrium, justifies the local biosynthesis of 
estrogen that promotes the growth of these lesions and possibly mediates the resistance to 
conventional hormonal treatments, which is observed in a number of women with 
endometriosis. The molecular mechanisms that are responsible for aberrant aromatase P450 
expression may provide insights into the etiology of endometriosis and lead to identification 
of molecular targets for the development of novel treatment strategies. Although 
endometrial aromatase P450 expression does not correlate with the disease stage, a recent 
study demonstrated that detection of aromatase P450 transcripts in the endometrium of 
endometriosis patients might be a potential qualitative marker of endometriosis.  
4.2 Hormone receptors 
The expression of receptors for the ovarian steroid hormones oestrogen and progesterone 
was studied immunohisto-chemically using monoclonal antibodies. The quantification of 
these receptors in the endometrium could be potentially useful in screening for this disease. 
The eutopic endometrium of patients with endometriosis is different from endometrium of 
fertile controls regarding apoptosis, cytokines and other characteristics. Although cyclic 
changes were also detected in ectopic endometrium, different patterns of receptor 
expression suggested a difference in hormonal regulation between the two sites.  
The concentrations of steroid receptors in ectopic endometrium increased gradually as the 
cycle progressed. Compared with eutopic endometrium, oestrogen and progesterone 
receptor concentrations were significantly lower in the proliferative phase, similar in the 
early secretory phase and significantly higher in the late secretory phase. The different 
patterns of receptor expression suggested different hormonal regulations between eutopic 
and ectopic endometrium.  
There are two isoforms for oestrogen (ER) and progesterone (PR) receptors-ER-α and ER-β, 
PRA and PR-B. These isoforms exist in the endometrium and their function and content are 
different from one another. The different concentrations and biological activity of steroid 
receptor isoforms might lead to various hormonal responsiveness of ectopic endometrium. 
High concentrations of ER and PR in the ectopic endometrium during the secretory phase 
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could explain the high proliferative activity of endometriotic tissue in this phase. 
Conversely, a decrease in ER and PR expression in ectopic implants during the secretory 
phase might lead to diminished proliferation. The expression of oestrogen and progesterone 
receptors may be regarded as an index of differentiation of the endometriotic implant. 
Consequently, ER and PR receptors may be used as markers of the activity of all subtypes of 
endometriotic lesions. 
5. Genetic markers 
Several genetic abnormalities or mutations have been suggested that might be related to 
endometriosis. Many technological approaches can help identify possible genetic markers of 
endometriosis. A number of technologies have emerged to facilitate progress in this 
direction (Taylor et al., 2002). Gene based technologies includes subtractive cDNA 
hybridization and cDNA microarray techniques. 
5.1 Survivin gene expression 
In endometriotic lesions, although derived from normal endometrium, decreased 
expression of adhesion molecules and increased expression of proteolytic enzymes may 
contribute to establishment of endometrial glands and stroma at ectopic sites, likely as 
behaviour of cancer cells. Normal epithelial cells undergo apoptosis when they separate 
from their primary tissue. However, spontaneous apoptosis of ectopic endometrial tissue 
is impaired in women with endometriosis, and its decreased susceptibility to apoptosis 
might participate in the growth, survival, and invasion of endometriotic tissue. Although 
there have been some reports on the induction of apoptosis in endometriotic lesions, there 
is no consensus on the mechanism of escape from apoptosis in endometriosis, and little is 
known on the correlation between survival activity and invasive phenotype in 
endometriotic cells. Among the regulators of cell death, inhibitor of apoptosis (IAP) 
proteins has recently emerged as modulators of an evolutionarily conserved step in 
apoptosis, which may potentially involve the direct inhibition of terminal effector 
caspases 3 and 7.  
Survivin is a novel inhibitor of apoptosis and is expressed during fetal development and in 
cancer tissues, but its expression has not been reported in normal adult tissues or benign 
diseases. Survivin gene and protein expression was detected in normal human 
endometrium and that survivin could play an important role in physiological homeostasis 
during the normal menstrual cycle (Konno et al., 2000). The survivin is also expressed in 
ectopic endometriotic tissue; however, there has been no report on the biological 
significance of survivin in endometriosis, an aggressive tumour-like benign disease. 
5.2 p53 mutations 
Genomic alterations may represent important events in the development of endometriosis. 
Tumour suppressor genes play a role in the regulation of cell growth and prevention of 
carcinogenesis. The altered tumour suppressor genes might be related with the 
development of endometriosis. p53, a representative tumour suppressor, is involved in cell 
proliferation and progression of various tumour types (Akahane et al., 2007).  
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High frequency of p53 locus deletion was observed in the endometriosis specimens (Bischoff 
et al., 2002). The p53 protein abnormalities and chromosomal aberrations may be involved 
in malignant transformation of ovarian endometriosis (Mhawech et al., 2002). In contrast, 
some investigators have demonstrated the undetectable expression of p53 in the 
endometriosis specimens.  
Although the real role of p53 polymorphism has not been clarified, it deserves more 
attentions in the study of endometriosis and the development of gene therapy. However, the 
real roles of these p53 gene polymorphisms upon endometriosis remain to be clarified. 
Lager cohort recruitment is request for its further clarification. After the elucidation of these 
issues, some tumour suppressor gene polymorphisms might become useful markers to 
predict the future development of endometriosis as well as the development and 
intervention of genetic therapy. 
5.3 Polymorphisms 
Some genetic polymorphisms, involved in sex steroids biosynthesis and metabolism, may be 
reasonably associated with an increased risk of endometriosis. Specific genes with 
polymorphisms have been investigated for an association with endometriosis. Some 
association studies implicated GALT (a gene involved in galactose metabolism) and GSTM1 
and NAT2 (genes encoding for the detoxification enzymes) as possible disease susceptibility 
genes. Recent finding have added to the evidence for the involvement of GSTM1 and NAT2, 
but have cast doubt on the role of GALT. The CDKN1A gene codon 31-arginine/serine 
polymorphism is not associated with endometriosis. Polymorphisms of the arylhydrocarbon 
receptor (AHR) gene and related genes were examined, and in at least one study, no 
association was found.  
The endometriosis regresses after menopause or ovariectomy, suggesting it could depend 
on the production and metabolism of sex steroids (Kitawaki et al., 2002): high concentrations 
of estrogens were found in the endometriotic lesions, which grow and regress in an 
oestrogen-dependent way.  
The inheritable susceptibility to endometriosis justifies the growing interest in identifying 
genes and/or genetic polymorphisms that could lead to an increased risk of disease. 
Identifying these polymorphisms may open to their use as genetic biomarkers of 
endometriosis (Vietri et al., 2007a, 2007b). Some genetic polymorphisms, involved in sex 
steroids biosynthesis and metabolism, may be reasonably associated with an increased risk 
of endometriosis, like progesterone receptor (PR), AR, oestrogen receptor (AR), 17beta-
hydroxysteroid dehydrogenase type 1 (HSD17B1), cytochrome P450 subfamily 17 (CYP17) 
and cytochrome P450 subfamily 19 (CYP19) (Guo, 2006). No doubt this list is likely to 
increase over the years. The most widely used approach for the identification of 
endometriosis-predisposing genetic polymorphisms are the genetic association studies, by 
which genetic susceptibility polymorphisms are identified through the identification and 
assessment of the difference in allele/genotype frequencies between patients and control 
subjects. 
The CYP17 genotype contains a single nucleotide T>C polymorphism situated 34bp 
upstream of the translation initiation site. C allele may have great promoter activity, 
increasing the transcription of P450c17 alpha enzyme. This effect amplifies the production of 
www.intechopen.com
 
Current Insights and Future Advances in Endometriosis Diagnostics  431 
precursor androgens that are subsequently converted to estrogens. In fact, C allele is 
associated with high levels of estradiol in young women. CYP19 gene lies on chromosome 
15 and encodes cytochrome P450, a major component of aromatase. Aromatase is a key 
enzyme in the conversion of androgens to estrogens, and mediates the rate-limiting step in 
the metabolism of C19 androgens to estrogens. Different polymorphisms of CYP19 are 
present in the gene and have been related to variations of aromatase activity (Gennari et al., 
2004). A silent SNP, C1558T, corresponding to the 3’ untraslated region of the mRNA, has 
been correlated to the level of aromatase mRNA in breast tumour cells. Another 
polymorphism, GA at Val80, has been previously associated with breast cancer risk. Few 
studies have been published on the association between CYP17 T>C polymorphism with 
risk of endometriosis, showing controversial data. Some studies connected C1558T 
polymorphism with endometriosis risk (Huber et al., 2005), while no report relates Val80 
SNP to endometriosis.  
The CYP19 genotype may play a role in increased risk of endometriosis lying on an 
environmental and genetic background. The polymorphisms of CYP19 are significantly 
represented in Val80 and C1558T in patients affected with endometriosis. Despite 
endometriosis is a multifactorial disease, identifying Val80 and C1558T polymorphisms of 
CYP19 could help to comprehend the mechanisms of endometriosis. The assessment of 
these polymorphisms could help to anticipate the diagnosis or expect it in asymptomatic 
women to elaborate a follow up program. Other than that, a follow up by ultrasound and 
blood markers could be proposed in these patients, in order to define unclear symptoms 
such as dysmenorrhoea and chronic pelvic pain.  
6. Future scope 
Endometriosis is associated with genetic and immunological influences and exposure to 
environmental factors. It seems to result from a complex sequence of events in which 
multiple gene loci interact with each other and the environment to produce the disease 
phenotype, but thus far little is known about the candidate genes involved (Balow & 
Kennedy 2005). Because of this complexity, endometriosis is ideally suited as a target for 
genome wide scanning. Mutations and single-nucleotide polymorphisms (SNPs) have been 
identified in a number of genes that might confer susceptibility to endometriosis, but their 
precise role remains to be determined. 
Proteome analysis is now widely accepted as a complementary technology to genetic 
profiling and together enables a better understanding of diseases and the development of 
new treatments. Proteomics allows the simultaneous observation of alterations in protein 
expression that may be either a precursor to or causative in disease development or a 
consequence of the disease. These techniques check and identify proteins that are 
expressed differently in patients with endometriosis versus normal controls. More 
recently, protein arrays using antibodies enable the screening of thousands of proteins 
against one sample. In future, such arrays could measure the expressions of multiple 
proteins to reveal changes in their regulation and expression in disease states. 
Furthermore, by using protein chip arrays, differential analysis of protein expression in 
women with and without differential protein profiling technology can be developed into a 
powerful tool for endometriosis research. 
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The study of protein function and protein-protein interaction can clarify the biology of the 
disease more so than the application of genomics. This is because gene expression and 
biological effects are linked via complex protein synthesis and gene interaction pathways.  
Genomics includes hybridization techniques (e.g. differential colony hybridization), 
subtractive techniques (e.g. hybridization and representational difference analysis), gel-
based techniques (e.g. RNA arbitrarily primed or differential display), and sequencing 
based techniques (e.g. expression sequence tags and serial analysis of gene expression). 
Furthermore, the use of DNA microarrays allows the search for new gene expression 
markers of endometriosis by identifying differentially expressed genes in endometriosis 
implants compared with endometrial tissue. The aim of the technique is to identify changes 
in gene expression characterizing the disease state so that we can understand the disease’s 
progression and identify novel therapeutic targets. 
Apart from the better understanding of the pathophysiology and the metabolic pathways 
that lead to potential biomarkers for endometriosis, there are still issues to be clarified and 
applications to be achieved. Once a protein or small number of proteins have been shown to 
be differentially expressed in endometriosis, the next step will be to use this information to 
try to develop a non-invasive diagnostic test for endometriosis. This diagnostic test should 
ideally have good sensitivity and specificity as well as satisfactory positive and negative 
predicative values for the detection of endometriosis, and also be cost effective and readily 
available.  
Genetic markers that are prognostic for endometriosis can be genotyped early in life and 
could predict individual response to various risk factors and treatment. Genetic 
predisposition revealed by genetic analysis for susceptibility genes can provide an 
integrated assessment of the interaction between genotypes and environmental factors, 
resulting in synergistically increased prognostic value of diagnostic tests. Thus, pre-
symptomatic and early symptomatic genetic testing is expected to be the cornerstone of the 
paradigmatic shift from late surgical interventions to earlier preventative therapies. Thus, 
there is an urgent need for novel genetic markers that are predictive of endometriosis and 
endometriosis progression, particularly in treatment decisions for individuals who are 
recognized as having endometriosis. 
Such genetic markers may enable prognosis of endometriosis in much larger populations 
compared with the populations that can currently be evaluated by using existing risk factors 
and biomarkers.  
The availability of a genetic test may allow, for example, early diagnosis and prognosis of 
endometriosis, as well as clinical intervention to mitigate progression of the disease. The use 
of these genetic markers will also allow selection of subjects for clinical trials involving 
novel treatment methods.  
The discovery of genetic markers associated with endometriosis will further provide novel 
targets for therapeutic intervention or preventive treatments of endometriosis and enable 
the development of new therapeutic agents for treating endometriosis. 
7. Conclusions 
One of the main objectives of the gynaecologist is to diagnose endometriosis without the use 
of laparoscopy or laparotomy. Currently, laparoscopy offers the most specific and sensitive 
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technique for evaluating and monitoring endometriosis. Even so, microscopic or occult 
endometriosis may be misdiagnosed because of the inability to visualize some lesions. 
Attempts for early diagnosis and treatments of endometriosis have been weighed down by 
lack of proper methods to study and manage the disease. Furthermore, the need for non-
invasive diagnostic methods is evident because the laparoscopy is a surgical procedure with 
potentially dangerous risks.  
At present, there are no reliable markers for the diagnosis and prognosis of endometriosis 
and identification of serum and endometrial markers is decisive for disease diagnosis and 
follow-up of patients.  
The diagnostic laboratories are using new genomic and proteomic technologies to develop 
novel diagnostic and therapeutic approaches for endometriosis. These technologies will 
facilitate the generation of molecular expression profiles and then identifying potential gene 
and protein targets.  This will lead to available markers with high sensitivity and specificity 
for screening of endometriosis, then to the development of serum diagnostic tools, 
therapeutic strategies and prognosis markers.  
The combination of immunological discoveries and recent advances in DNA technologies 
may provide the long sought screening tool with the desirable diagnostic accuracy for this 
puzzling disorder. 
The identification of specific genetic alterations and protein profiles associated with 
endometriosis offers a unique opportunity to develop assays for early diagnosis and/or 
treatment. By identifying proteins in biological samples, a minimally invasive tool should be 
feasible to assess the presence of disease and monitor response to treatment and/or disease 
progression.  
The promise for gene-based diagnostic tests for endometriosis and rational development of 
genetically targeted and molecular therapeutic strategies is, in principle, excellent. The 
evolving genomic and proteomic technologies remain poised to revolutionize the diagnosis 
and treatment of endometriosis, but have not yet lead to a single new therapy or tested 
biomarker. Many problems remain to be resolved and, while some of these are technical in 
nature, the most intractable ones have mainly to do with the complex and multifactorial 
character of the disease itself. 
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